Polatuzumab vedotin plus obinutuzumab plus venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.
JOURNAL OF CLINICAL ONCOLOGY(2021)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY(2021)